The Hindu Business Line : Within patent regime ambit: Novartis

MUMBAI: The pre-grant opposition filed by Natco against Novartis' patent application for its blood cancer drug is within the ambit of the new patent regime, said Mr Ranjit Shahani, Vice-Chairman and Managing Director of Novartis India.

While pre-grant opposition may be the landscape for the future, he said the case would be heard on its merit, by the patent controllers office. Novartis is supporting about 4,000 cancer patients who need Glivec and the company has spent about $100 million (Rs 435 crore) on the India programme, said Mr Shahani.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Kanda Motors to launch more 2-wheeler models

Ambani brothers' gesture

Settlement to benefit shareholders: Kampani

Natco challenges Novartis' patent on anti-cancer drug

Within patent regime ambit: Novartis

Govt may seek GDR end-use details from Morepen

BILT launches $60-m FCCB issue

HC likely to finalise Standard Motors' property sale issue

Two firms get HC order to recover monies from HMA

ICAR management programme in Hyderabad

Bengal bars Haldia Petro from taking part in Basell acquisition

Venus bets on new combination drugs

New Holland Tractors to launch two new models this year

Alex Kuruvilla quits as chief of MTV India

Schuster quits Skoda